TY - JOUR
T1 - Regulation of Alzheimer β-amyloid precursor trafficking and metabolism
AU - Gandy, Sam
AU - Petanceska, Suzana
N1 - Funding Information:
This work was supported by the USPHS, the New York State Office of Mental Health and the Research Foundation for Mental Hygiene. S.G. receives or has received honoraria and/or extramural support from the Women’s Health Research Institute of Wyeth-Ayerst Pharmaceuticals (a division of American Home Corporation), Warner Lambert/Parke-Davis Pharmaceuticals, Hoffman La Roche Pharmaceuticals and Neurogen Corporation.
PY - 2000/7/26
Y1 - 2000/7/26
N2 - Alzheimer's disease (AD) is characterized by the intracranial accumulation of the 4 kDa amyloid-β peptide (Aβ), following proteolysis of a ~700-amino acid, integral membrane precursor, the Alzheimer amyloid precursor protein (APP). The best evidence causally linking APP to AD has been provided by the discovery of mutations within the APP coding sequence that segregate with disease phenotypes in autosomal dominant forms of familial AD (FAD). Though FAD is rare (<10% of all AD), the hallmark features (amyloid plaques, neurofibrillary tangles, synaptic and neuronal loss, neurotransmitter deficits and dementia) are indistinguishable when FAD is compared with typical, common, 'non-familial', or sporadic, AD (SAD). Studies of some clinically relevant mutant APP molecules from FAD families have yielded evidence that APP mutations can lead to the enhanced generation or aggregability of Aβ, consistent with a pathogenic role in AD. Other genetic loci for FAD have been discovered which are distinct from the immediate regulatory and coding regions of the APP gene, indicating that defects in molecules other than APP can also specify cerebral amyloidogenesis and FAD. To date, all APP and non-APP FAD mutations can be demonstrated to have the common feature of promoting amyloidogenesis of Aβ. Epidemiological studies indicate that postmenopausal women on estrogen replacement therapy (ERT) have their relative risk of developing SAD diminished by about one third as compared with age-matched women not receiving ERT [M.X. Tang, D. Jacobs, Y. Stern, K. Marder, P. Schofield, B. Gurland, H. Andrews, R. Mayeux, Effect of estrogen during menopause on risk and age at onset of Alzheimer's disease, Lancet 348 (2000) 429-432]. Because of the key role of cerebral Aβ accumulation in initiating AD pathology, it is most attractive that estradiol might modulate SAD risk or age-at-onset by inhibiting Aβ accumulation. A possible mechanistic basis for such a scenario is reviewed here. Copyright (C) 2000 Elsevier Science B.V.
AB - Alzheimer's disease (AD) is characterized by the intracranial accumulation of the 4 kDa amyloid-β peptide (Aβ), following proteolysis of a ~700-amino acid, integral membrane precursor, the Alzheimer amyloid precursor protein (APP). The best evidence causally linking APP to AD has been provided by the discovery of mutations within the APP coding sequence that segregate with disease phenotypes in autosomal dominant forms of familial AD (FAD). Though FAD is rare (<10% of all AD), the hallmark features (amyloid plaques, neurofibrillary tangles, synaptic and neuronal loss, neurotransmitter deficits and dementia) are indistinguishable when FAD is compared with typical, common, 'non-familial', or sporadic, AD (SAD). Studies of some clinically relevant mutant APP molecules from FAD families have yielded evidence that APP mutations can lead to the enhanced generation or aggregability of Aβ, consistent with a pathogenic role in AD. Other genetic loci for FAD have been discovered which are distinct from the immediate regulatory and coding regions of the APP gene, indicating that defects in molecules other than APP can also specify cerebral amyloidogenesis and FAD. To date, all APP and non-APP FAD mutations can be demonstrated to have the common feature of promoting amyloidogenesis of Aβ. Epidemiological studies indicate that postmenopausal women on estrogen replacement therapy (ERT) have their relative risk of developing SAD diminished by about one third as compared with age-matched women not receiving ERT [M.X. Tang, D. Jacobs, Y. Stern, K. Marder, P. Schofield, B. Gurland, H. Andrews, R. Mayeux, Effect of estrogen during menopause on risk and age at onset of Alzheimer's disease, Lancet 348 (2000) 429-432]. Because of the key role of cerebral Aβ accumulation in initiating AD pathology, it is most attractive that estradiol might modulate SAD risk or age-at-onset by inhibiting Aβ accumulation. A possible mechanistic basis for such a scenario is reviewed here. Copyright (C) 2000 Elsevier Science B.V.
KW - Alzheimer β-amyloid precursor
KW - Metabolism
KW - Regulation
KW - Trafficking
UR - https://www.scopus.com/pages/publications/0034718231
U2 - 10.1016/S0925-4439(00)00031-4
DO - 10.1016/S0925-4439(00)00031-4
M3 - Review article
C2 - 10899430
AN - SCOPUS:0034718231
SN - 0925-4439
VL - 1502
SP - 44
EP - 52
JO - Biochimica et Biophysica Acta - Molecular Basis of Disease
JF - Biochimica et Biophysica Acta - Molecular Basis of Disease
IS - 1
ER -